ATE549404T1 - Verfahren zum screening eines transmembranenzymhemmstoffs - Google Patents
Verfahren zum screening eines transmembranenzymhemmstoffsInfo
- Publication number
- ATE549404T1 ATE549404T1 AT05790422T AT05790422T ATE549404T1 AT E549404 T1 ATE549404 T1 AT E549404T1 AT 05790422 T AT05790422 T AT 05790422T AT 05790422 T AT05790422 T AT 05790422T AT E549404 T1 ATE549404 T1 AT E549404T1
- Authority
- AT
- Austria
- Prior art keywords
- transmembrane
- enzyme
- protein
- region
- inhibitor
- Prior art date
Links
- 238000012216 screening Methods 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 title 1
- 102100034866 Kallikrein-6 Human genes 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 7
- 108090000790 Enzymes Proteins 0.000 abstract 7
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004290784 | 2004-10-01 | ||
| PCT/JP2005/018587 WO2006038684A1 (ja) | 2004-10-01 | 2005-09-30 | 膜貫通型酵素阻害物質のスクリーニング方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE549404T1 true ATE549404T1 (de) | 2012-03-15 |
Family
ID=36142754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05790422T ATE549404T1 (de) | 2004-10-01 | 2005-09-30 | Verfahren zum screening eines transmembranenzymhemmstoffs |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080220445A1 (de) |
| EP (1) | EP1801232B1 (de) |
| JP (1) | JP4778906B2 (de) |
| AT (1) | ATE549404T1 (de) |
| WO (1) | WO2006038684A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201390669A1 (ru) | 2010-11-10 | 2013-11-29 | Дженентек, Инк. | Способы и композиции для иммунотерапии заболеваний нервной системы |
| US11008403B2 (en) | 2014-11-19 | 2021-05-18 | Genentech, Inc. | Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use |
| EP3221364B1 (de) | 2014-11-19 | 2020-12-16 | Genentech, Inc. | Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen |
| CN107475260B (zh) * | 2017-09-08 | 2020-12-04 | 东北师范大学 | 抑制大脑中Aβ累积的BACE1亚型的功能研发及应用 |
| CN107523579A (zh) * | 2017-09-08 | 2017-12-29 | 东北师范大学 | 促进大脑中Aβ累积的BACE1亚型的功能研发及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE667959T1 (de) | 1992-10-26 | 2000-04-20 | Dale B Schenk | VERFAHREN UND ZUSAMMENSETZUNGEN FÜR DEN NACHWEIS VON LÖSLICHEM-g(b)-AMYLOIDPEPTID. |
| NZ264143A (en) | 1993-08-09 | 1996-11-26 | Lilly Co Eli | Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production |
| WO1999043711A1 (en) * | 1998-02-27 | 1999-09-02 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | G protein-coupled receptor antagonists |
| US6699671B1 (en) | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
| ATE440110T1 (de) * | 1998-10-26 | 2009-09-15 | Genzyme Corp | Zusammensetzungen und verfahren zur behandlung der polyzystischen nierenkrankheit |
| JP2002037731A (ja) * | 2000-05-19 | 2002-02-06 | Takeda Chem Ind Ltd | βセクレターゼ阻害剤 |
| CN1251671C (zh) | 2000-05-19 | 2006-04-19 | 武田药品工业株式会社 | β分泌酶抑制剂 |
| US20030095958A1 (en) | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
| US6562783B2 (en) | 2001-05-30 | 2003-05-13 | Neurologic, Inc. | Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors |
| CH698246B1 (de) * | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. |
| CA2471531A1 (en) * | 2001-12-26 | 2003-07-10 | Takeda Chemical Industries, Ltd. | Agents for treating mild cognitive impairment |
-
2005
- 2005-09-30 AT AT05790422T patent/ATE549404T1/de active
- 2005-09-30 EP EP05790422A patent/EP1801232B1/de not_active Expired - Lifetime
- 2005-09-30 WO PCT/JP2005/018587 patent/WO2006038684A1/ja not_active Ceased
- 2005-09-30 US US11/664,086 patent/US20080220445A1/en not_active Abandoned
- 2005-09-30 JP JP2006539339A patent/JP4778906B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006038684A1 (ja) | 2006-04-13 |
| EP1801232A4 (de) | 2008-12-10 |
| EP1801232B1 (de) | 2012-03-14 |
| US20080220445A1 (en) | 2008-09-11 |
| EP1801232A1 (de) | 2007-06-27 |
| JP4778906B2 (ja) | 2011-09-21 |
| JPWO2006038684A1 (ja) | 2008-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE496021T1 (de) | Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen | |
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| EA200100992A1 (ru) | Ингибиторы фермента impdh | |
| NO20073628L (no) | Pyridoner som er nyttige som inhibitorer av kinaser | |
| ATE396731T1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| ATE556711T1 (de) | Verfahren zur verbesserung der hautqualität | |
| CY1108689T1 (el) | Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα | |
| PT966465E (pt) | Inibidores do enzima imfdh | |
| EA200700117A1 (ru) | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов | |
| NO20074697L (no) | Ikke-aromatisk, nitrogenholdig heterosyklisk-1-karboksylatester-pyridylderivat | |
| EA200701257A1 (ru) | Пирролопиразолы в качестве сильнодействующих ингибиторов киназы | |
| BRPI0511111A (pt) | compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários | |
| ATE359773T1 (de) | Verfahren zur behandlung von erkrankungen mit malonyl coa-decarboxylase-inhibitoren | |
| CY1110185T1 (el) | Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19 | |
| WO2005119251A3 (en) | Novel means and methods for the treatment of hearing loss and phantom hearing | |
| MA29554B1 (fr) | Nouveaux derives d'amide d'acide piperidine carboxylique | |
| DE60336217D1 (de) | Verfahren zur bestimmung von enzym aktivität | |
| DE602005012481D1 (de) | 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck | |
| WO2003095475A8 (en) | Peptide compounds and their use as protease substrates | |
| WO2003099202A3 (en) | Beta-secretase inhibitors | |
| ATE549404T1 (de) | Verfahren zum screening eines transmembranenzymhemmstoffs | |
| WO2006034296A3 (en) | Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof | |
| NO20061575L (no) | Fremgangsmate for fremstilling av renzapride og mellomprodukter derav | |
| WO2006094201A3 (en) | Semicarbazide-sensitive amide oxidase inhibitors | |
| DE602005022693D1 (de) | Krebsdiagnose und behandlung unter verwendung eines anti-robo1-antikörpers |